The O'Leary‐Sant Interstitial Cystitis Symptom Index is a clinically useful indicator of treatment outcome in patients with interstitial cystitis/bladder pain syndrome with Hunner lesions: A post hoc analysis of the Japanese phase III trial of KRP‐116D, 50% dimethyl sulfoxide solution

Paper link corrected: https://bonoi.org/index.php/si/article/view/636 It has been brought to authors attention that there is a missing part in “Materials and Methods” of the Systematic Review article by Xiao et al., entitled “Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis” in the Volume 39, No. 4 of Science Insights (pp.363-373). The missing part of the “Materials and Methods” is as below: Population: Patients with IC/BPS.Intervention: All patients underwent intravesical HA and/or CS treatment regimen.Comparison: Improvement in symptoms pre-treatment and post-treatment or other treatment regimen.Outcome: The primary outcome was the change in visual analogue scale (VAS) for pain symptom from baseline to the follow-up period; secondary outcomes were the changes in total scores of the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), storage symptoms including frequency and urgency, and bladder capacity.

Download Full-text

Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis

Canadian Urological Association Journal ◽

10.5489/cuaj.2036 ◽

2014 ◽

Vol 8 (9-10) ◽

pp. 610 ◽

Cited By ~ 15

Author(s):

Ömer Gülpınar ◽

Aytaç Kayış ◽

Evren Süer ◽

Mehmet İlker Gökçe ◽

Adil Güçal Güçlü ◽

...

Keyword(s):

Hyaluronic Acid ◽

Interstitial Cystitis ◽

Chondroitin Sulphate ◽

Sodium Hyaluronate ◽

Previous Treatment ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Symptom Index ◽

Bladder Pain ◽

Significant Difference

Introduction: Patients with a history of bladder pain syndrome/interstitial cystitis (BPS/IC) and who responded poorly or unsatisfactorily with previous treatment were compared taking intravesical hyaluronic acid (HA) or hyaluronic acid-chondroitin sulphate (HA-CS).Methods: Patients were treated with intravesical instillation with 50 mL sterile sodium hyalurinic acid (Hyacyst, Syner-Med, Surrey, UK) (n = 32) and sodium hyaluronate 1.6% sodium chondroitin sulphate 2% (Ialuril, Aspire Pharma, UK) (n = 33). Intravesical instillations were performed weekly in first month, every 15 days in the second month and monthly in third and fourth months, for a total of 8 doses. Patients were evaluated using a visual analog pain scale (VAS), interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), voiding diary for frequency/nocturia, cystometric bladder capacity and voided volume at the beginning and at 6 months. All patients had a potassium sensitivity test (PST) initially. Wilcoxon and Mann-Whitney U tests were used for statistical analysis.Results: In total, 53 patients met the study criteria. There were 30 patients in the HA-CS group (mean age: 48.47) and 23 patients in the HA group (mean age: 49.61) (p > 0.05). The initial PST was positive in 71.7% patients (38/53) overall with no difference between groups (p > 0.05). Responses for VAS, ICCS, ICPS, 24-hour frequency/nocturia statistically improved in both groups at 6 months. There was no significant difference in symptomatic improvement (p > 0.05). Eight patients had mild adverse events.Conclusion: HA and HA/CS instillation can be effective in BPS/IC patients who do not respond to conservative treatment. An important limitation of our study is that the HA dosage of the 2 treatment arms were different. It would be more appropriate with same HA dosage in both groups; however, there was no commercially available glycosaminoglycan (GAG) substance with same HA dosage for single and combination therapy. Large, long-term randomized studies are required to determine if there is a difference between these treatments.

Download Full-text

Mirabegron as adjuvant treatment for patients with interstitial cystitis/bladder pain syndrome

Canadian Urological Association Journal ◽

10.5489/cuaj.4325 ◽

2017 ◽

Vol 12 (3) ◽

pp. E100-4 ◽

Cited By ~ 2

Author(s):

Michael Di Lena ◽

Victoria Tolls ◽

Kerri-Lynn Kelly ◽

J. Curtis Nickel

Keyword(s):

Interstitial Cystitis ◽

Adjuvant Treatment ◽

Treatment Options ◽

Pain Syndrome ◽

Bladder Pain Syndrome ◽

Post Treatment ◽

Symptom Scale ◽

Symptom Index ◽

Bladder Pain ◽

Significant Difference

Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) patients represent a heterogeneous group with pain and urinary storage symptoms and varying responses to current treatment options. The novel beta-3 agonist, mirabegron, has been shown to improve storage symptoms of patients with bladder overactivity; however, its effect on symptoms in the IC/BPS population has yet to be studied.Methods: Patients diagnosed at a single IC centre with IC/BPS undergoing standard therapy were treated with additional daily mirabegron 25 mg and seen in followup post-treatment. Patients completed the Interstitial Cystitis Symptom Index and Problem Index (ICSI/ICPI), and the Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) prior to and following mirabegron treatment. Global (NRS) and symptom-specific outcomes were assessed by comparing the pre- and post-treatment mean scores using tailed-t test (p<0.05 considered statistically significant).Results: A total of 23 patients were available for review pre- and post-mirabegron treatment. There was no significant difference in ICSI (p=0.448), ICPI (p=0.352), or PUF (p=0.869) pre- and post-treatment. Analysis of symptom-specific outcomes show statistically significant improvements in urgency (p=0.048); however, no statistically significant improvements in frequency (p=0.951) or pain (p=0.952) were observed with mirabegron therapy.Conclusions: IC/BPS patients treated with mirabegron had improvement of urinary urgency, but no significant benefit in terms of pain or urinary frequency. This data suggests that mirabegron’s role in the IC/BPS patient should be that of adjuvant treatment to ameliorate urgency.

Download Full-text